Thursday, June 29, 2017

FedNet

The multimedia news leader in Washington since 1996.

Prescription Drug Pricing

House Oversight and Government Reform Committee

Developments in the Prescription Drug Market: Oversight

Thursday February 4, 2016 9:00 a.m.

Room: 2154 Rayburn Bldg.

Ms. Janet Woodcock, Director, Food and Drug Administration - Center for Drug Evaluation and Research

Mr. Howard Schiller, Interim CEO, Valeant Pharmaceuticals International, Inc.

Mr. Martin Shkreli, Former CEO, Turing Pharmaceuticals LLC

Ms. Nancy Retzlaff, Chief Commercial Officer, Turing Pharmaceuticals LLC

Mr. Mark Merritt, President and CEO, Pharmaceutical Care Management Association